T. Rowe Price Investment Management
CNTA

T. Rowe Price Investment Management’s Centessa Pharmaceuticals CNTA Stock Holding History

T. Rowe Price Investment Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.75M Buy
170,016
+168,480
+10,969% +$4.31M ﹤0.01% 552
2025
Q4 		$39K Buy
1,536
+1,516
+7,580% +$38.4K ﹤0.01% 674
2025
Q3 		$1K Sell
20
-381
-95% -$6.77K ﹤0.01% 869
2025
Q2 		$6K Sell
401
-1,752,847
-100% -$22.2M ﹤0.01% 681
2025
Q1 		$25.2M Sell
1,753,248
-1,665,352
-49% -$27.3M 0.02% 491
2024
Q4 		$57.3M Sell
3,418,600
-137,423
-4% -$2.28M 0.04% 388
2024
Q3 		$56.9M Buy
3,556,023
+2,722,030
+326% +$33.3M 0.03% 388
2024
Q2 		$7.53M Buy
+833,993
New +$7.91M ﹤0.01% 556

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management's CNTA Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Centessa Pharmaceuticals (CNTA) stake by 10,969% in Q1 2026, buying an estimated $4.31M and bringing the position to 170,016 shares worth $6.75M. The position accounts for ﹤0.01% of the portfolio, ranked #552.

T. Rowe Price Investment Management first reported a position in CNTA in Q2 2024 and has held it in 8 quarters since. The position peaked at $57.3M in Q4 2024. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • T. Rowe Price Investment Management held 170,016 shares of Centessa Pharmaceuticals worth $6.75M as of Q1 2026.
  • T. Rowe Price Investment Management bought 168,480 Centessa Pharmaceuticals shares in Q1 2026, an estimated $4.31M.
  • Centessa Pharmaceuticals made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #552 holding.
  • T. Rowe Price Investment Management first reported a position in Centessa Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • T. Rowe Price Investment Management's Centessa Pharmaceuticals position peaked at $57.3M in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.